Turbine announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd. to identify and validate novel targets within one of Ono?s priority domains of cancer biology. Under the terms of the agreement, Turbine will apply its end-to-end, interpretable cell simulation technology, the Simulated Cell? platform, to the in silico discovery of novel targets for potential therapeutic development.

Turbine will also conduct in vitro mechanism validation of identified targets in its laboratory facility and manage in vivo validation studies. Turbine will receive payments upon execution of the agreement and for the completion of the target identification screen on its platform including in vitro and in vivo validation. Additionally, Turbine will be eligible for milestone payments based on the progress of drug development and commercialization by Ono.